PSI-7977 - second half of 2013.

No Interferon in Phase 3 Trials of Hep C Drug PSI-7977

November 4, 2011

Based on previous encouraging results, Pharmasett’s PSI-7977 will begin Phase 3 testing in three distinct Hepatitis C trials – all without interferon.

November 1, 2011

Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies

Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage clinical trials exploring the drug’s safety and efficacy as a component of a regimen that only needs to be taken for three months and that doesn’t include pegylated interferon, according to a November 1 announcement by the company. If all goes well in the studies, the company will petition the U.S. Food and Drug Administration (FDA) to begin the process of reviewing PSI-7977 for approval sometime in the second half of 2013.

Continue reading this entire article:
http://www.aidsmeds.com/articles/pharmasset_psi7977_trials_1667_21386.shtml

Posted by Editors on November 4, 2011

Requirements for using and reposting articles

FONTE:

http://www.hepatitis-central.com/mt/archives/2011/11/no_interferon_i.html


TRADUÇÃO:

http://translate.google.com/translate?sl=en&tl=pt&js=n&prev=_t&hl=pt-PT&ie=UTF-
8&eotf=1&u=http%3A%2F%2Fwww.hepatitis-central.com%2Fmt%2Farchives%2F2011%2F11%2Fno_interferon_i.html